ASLAN PHARMACEU/ADR (NASDAQ:ASLN) Expected to Announce Earnings of -$0.16 Per Share

Share on StockTwits

Wall Street brokerages forecast that ASLAN PHARMACEU/ADR (NASDAQ:ASLN) will report ($0.16) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for ASLAN PHARMACEU/ADR’s earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.15). ASLAN PHARMACEU/ADR reported earnings per share of ($0.35) in the same quarter last year, which suggests a positive year over year growth rate of 54.3%. The firm is scheduled to issue its next quarterly earnings results on Friday, March 27th.

According to Zacks, analysts expect that ASLAN PHARMACEU/ADR will report full-year earnings of ($0.69) per share for the current fiscal year, with EPS estimates ranging from ($0.70) to ($0.68). For the next financial year, analysts expect that the firm will report earnings of ($0.62) per share, with EPS estimates ranging from ($0.79) to ($0.53). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for ASLAN PHARMACEU/ADR.

ASLAN PHARMACEU/ADR (NASDAQ:ASLN) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.19.

A number of research firms have weighed in on ASLN. Zacks Investment Research raised shares of ASLAN PHARMACEU/ADR from a “hold” rating to a “strong-buy” rating and set a $2.00 target price on the stock in a research note on Monday, November 4th. HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of ASLAN PHARMACEU/ADR in a research note on Monday, November 25th. Piper Jaffray Companies upgraded ASLAN PHARMACEU/ADR from a “neutral” rating to an “overweight” rating and set a $8.00 price target for the company in a research note on Monday. Finally, BTIG Research downgraded ASLAN PHARMACEU/ADR from a “buy” rating to a “neutral” rating in a report on Monday, November 11th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $4.00.

NASDAQ:ASLN traded down $2.58 on Tuesday, hitting $2.62. The company had a trading volume of 8,323,882 shares, compared to its average volume of 320,279. The stock has a market capitalization of $122.43 million, a price-to-earnings ratio of -1.87 and a beta of 3.31. The company has a current ratio of 1.88, a quick ratio of 3.80 and a debt-to-equity ratio of 1.12. The firm has a 50 day moving average of $1.68 and a two-hundred day moving average of $2.48. ASLAN PHARMACEU/ADR has a 52 week low of $0.35 and a 52 week high of $8.18.

A hedge fund recently raised its stake in ASLAN PHARMACEU/ADR stock. FNY Investment Advisers LLC boosted its holdings in ASLAN PHARMACEU/ADR (NASDAQ:ASLN) by 57.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,100 shares of the company’s stock after buying an additional 6,993 shares during the quarter. FNY Investment Advisers LLC owned approximately 0.06% of ASLAN PHARMACEU/ADR worth $33,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 7.12% of the company’s stock.

About ASLAN PHARMACEU/ADR

ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.

See Also: Retained Earnings

Get a free copy of the Zacks research report on ASLAN PHARMACEU/ADR (ASLN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ASLAN PHARMACEU/ADR (NASDAQ:ASLN)

Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.